AC Immune (ACIU) CFO discloses common shares, RSUs and option grants
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
AC Immune SA’s Chief Financial Officer Christopher James Roberts has filed an initial statement of holdings. He reports direct ownership of 155,382 common shares, which the footnotes state includes 109,564 common shares underlying outstanding restricted share units. He also reports a series of share options to buy common shares with exercise prices ranging from 2.32 to 6.88 and expirations between 2029 and 2035. One option grant is fully vested, while others vest in twelve substantially equal quarterly installments beginning on March 31, 2024, March 31, 2025, and March 31, 2026.
Positive
- None.
Negative
- None.
Insider Trade Summary
9 transactions reported
Mixed
9 txns
Insider
Roberts Christopher James
Role
Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Common Shares | -- | -- | -- |
Holdings After Transaction:
Share Option (right to buy) — 7,200 shares (Direct);
Common Shares — 155,382 shares (Direct)
Footnotes (1)
- Includes 109,564 common shares underlying outstanding restricted share units. The share option is fully vested. The share option vests in twelve substantially equal quarterly installments beginning on March 31, 2024. The share option vests in twelve substantially equal quarterly installments beginning on March 31, 2025. The share option vests in twelve substantially equal quarterly installments beginning on March 31, 2026.
